Clinical Podcasts

UpToDate faculty discuss important “What’s New” and “Practice Changing UpDates”, based on recent medical journal articles, in our clinical podcasts. Our contributors are recognized physician leaders in their fields and offer their expertise regarding each update and its impact on clinical practice. Each clinical podcast includes the most current clinical information available as of the release date listed.

Support for UpToDate Talk is provided by UpToDate, Wolters Kluwer. UpToDate is entirely funded by the subscriptions of its users and does not accept advertising or funding unrelated to subscriptions. The opinions in such podcasts are entirely those of the discussants, and these discussants are authors and editors for UpToDate. View the UpToDate conflict of interest policy.

To be alerted as each new episode airs, simply subscribe to our podcast channel on iTunes. Also, check out our Healthcare Industry Podcasts that explore healthcare initiatives with an impact on quality and patient safety. We hope you will find these series an enjoyable way to keep UpToDate!

Options for treatment of localized prostate cancer; Drug-eluting & bare metal intracoronary stents

Date Released: Nov 9 2016

This episode features Dr. Jerome Richie, discussing options for treatment of localized low-risk prostate cancer (starts at 00:42); and Dr. Donald Cutlip, discussing comparison of current generation drug-eluting and bare metal intracoronary stents (starts at 14:30).

Listen to the full podcast by pressing the Play Button below, or jump to the segment on the treatment of localized low-risk prostate cancer or the segment on the comparison of drug-eluting and bare metal intracoronary stents.

Dr. RichieDr. Jerome Richie is Professor of Surgery at the Harvard Medical School and Emeritus Chief of Urology at Brigham and Women’s Hospital in Boston.
Dr. CutlipDr. Donald Cutlip is Professor of Medicine at the Harvard Medical School and Director of the Cardiac Catheterization Laboratory at the Beth Israel Deaconess Medical Center.

Segment on prostate cancer (Dr. Richie):

  1. Hamdy FC, Donovan JL, Lane JA, et al. 10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer. N Engl J Med 2016; 375:1415.
  2. Donovan JL, Hamdy FC, Lane JA, et al. Patient-Reported Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer. N Engl J Med 2106; 375:1425.

Segment on drug-eluting & bare metal intracoronary stents (Dr. Richie):

  1. Bønaa KH, Mannsverk J, Wiseth R, et al. Drug-Eluting or Bare-Metal Stents for Coronary Artery Disease. N Engl J Med 2016; 375:1242.

Close

Jerome P Richie, MD, FACS Employment: Metamark Genetics [Prostate cancer healthcare delivery] - No relevant conflict on topic.

Donald Cutlip, MD Grant/Research/Clinical Trial Support: Boston Scientific [Transcatheter aortic valve; coronary artery stent]; Medtronic [Coronary stent (Drug-eluting stent)].

Close

Early benefit of aspirin after TIA or ischemic stroke; HIV treatment to prevent sexual transmission

Date Released: Oct 26 2016

This episode features Dr. Brett Cucchiara discussing aspirin for secondary prevention after transient ischemic attack or stroke (starts at 01:28); and Dr. Paul Sax discussing the prevention of HIV1 transmission with antiretroviral therapy (starts at 16:50). Dr. Helen Hollingsworth hosts.

Listen to the full podcast by pressing the Play Button below, or jump to the segment on early benefit of aspirin after TIA or ischemic stroke or the segment on HIV treatment to prevent sexual transmission.

Dr. CucchiaraDr. Brett Cucchiara is Associate Professor of Neurology at the Hospital of the University of Pennsylvania.
Dr. SaxDr. Paul Sax is Professor of Medicine at Harvard Medical School and Clinical Director of Infectious Disease at Brigham and Women’s Hospital in Boston.

Segment on aspirin after TIA or ischemic stroke (Dr. Cucchiara):

  1. Rothwell PM, Algra A, Chen Z, et al. Effects of aspirin on risk and severity of early recurrent stroke after transient ischaemic attack and ischaemic stroke: time-course analysis of randomised trials. Lancet 2016; 388:365.

Segment on HIV treatment (Dr. Paul Sax):

  1. Cohen MS, Chen YQ, McMauley M, et al. Antiretroviral therapy for the prevention of HIV-1 transmission. N Engl J Med 2016.

Close

Brett L Cucchiara, MD Grant/Research Support: Bristol Myers Squibb [Stroke (Clopidogrel)]. Consultant/Advisory Boards: Boehringer Ingelheim [Stroke (Dabigatran)]; AstraZeneca [Stroke (Ticagrelor)].

Paul E Sax, MD Grant/Research/Clinical Trial Support: Bristol-Myers Squibb [HIV (Atazanavir, efavirenz)]; Gilead Sciences [HIV (Tenofovir, emtricitabine, elvitegravir, cobicistat, ledipasvir, sofosbuvir)]; GlaxoSmithKline [HIV (lamivudine, abacavir, dolutegravir)]. Consultant/Advisory Board: AbbVie [HIV (Lopinavir, ritonavir)]; Bristol-Myers Squibb [HIV (Atazanavir, efavirenz)]; Gilead Sciences [HIV (Tenofovir, emtricitabine, elvitegravir, cobicistat, ledipasvir, sofosbuvir)]; GlaxoSmithKline [HIV (lamivudine, abacavir, dolutegravir)]; Janssen Pharmaceuticals [HIV (Darunavir, etravirine, rilpivirine)]; Merck & Co., Inc.[HIV (raltegravir)].

Close

Choice of influenza vaccines for 2016-2017 season; Complications of dopamine agonists for RLS

Date Released: Oct 12 2016

This episode features Dr. Martin Hirsch discussing choice of influenza vaccines for the 2016-17 season in the northern hemisphere (starts at 00:35); and Dr. Alon Avidan discussing the diagnosis and management of augmentation, a condition seen in patients with restless legs syndrome who have been treated with dopamine agonists (starts at 13:37). Dr. Nancy Sokol hosts.

Listen to the full podcast by pressing the Play Button below, or jump to the segment on choice of influenza vaccines for 2016-2017 season or the segment on complications of dopamine agonists for RLS.

Dr. HirschDr. Martin Hirsch is Professor of Medicine at the Harvard Medical School, Professor of Infectious Diseases and Immunology at the Harvard School of Public Health, and Senior Physician in Infectious Diseases at the Massachusetts General Hospital in Boston.
Dr. AvidanDr. Alon Avidan is Professor of Neurology at the David Geffen School of Medicine at UCLA and Director of the UCLA Sleep Disorders Center.

Segment on influenza vaccines (Dr. Hirsch):

  1. Centers for Disease Control and Prevention. ACIP votes down use of LAIV for 2016-2017 flu season. http://www.cdc.gov/media/releases/2016/s0622-laiv-flu.html (Accessed on June 24, 2016).
  2. Hawkes N. UK stands by nasal flu vaccine for children as US doctors are told to stop using it. BMJ 2016; 353:i3546.
  3. AstraZeneca provides update on Flumist quadrivalent vaccine in the US for the 2016-2017 influenza season. https://www.astrazeneca.com/media-centre/press-releases/2016/astrazeneca-provides-update-on-flumist-quadrivalent-vaccine-in-the-us-for-the-2016-17-influenza-season-23062016.html (Accessed on June 27, 2016).
  4. Influenza vaccine effectiveness (VE) in adults and children in primary care in the UK: provisional end-of-season results 2015-2016. https://www.gov.uk/government/publications/influenza-vaccine-effectiveness-2015-to-2016-estimates (Accessed on June 27, 2016).
  5. Seasonal childhood influenza vaccinations. Experiences from Finland. http://www.nvm2016.is/sites/default/files/Nohynek_NorVac_influenzaLessonsNohynek_short.pdf (Accessed on June 27, 2016).
Segment on restless legs syndrome (Dr. Avidan):
  1. Garcia-Borreguero D, Silber MH, Winkelman JW, et al. Guidelines for the first-line treatment of restless legs syndrome/Willis-Ekbom disease, prevention and treatment of dopaminergic augmentation: a combined task force of the IRLSSG, EURLSSG, and the RLS-foundation. Sleep Med 2016; 21:1.

Close

Martin S Hirsch, MD Nothing to disclose

Alon Avidan, MD Speaker's Bureau: Xenoport [Restless legs syndrome (Horizant)]; Merck [Insomnia (Suvorexant)].

Close

Sofosbuvir-velpatasvir for chronic HCV infection; Neonatal phototherapy & risk of childhood cancer

Date Released: Sep 28 2016

This episode features Dr. Adrian Di Bisceglie discussing a Practice Changing UpDate related to sofosbuvir-velpatasvir for treatment of chronic HCV infection (starts at 00:51); and Dr. Vinod Bhutani discussing neonatal phototherapy and risk of childhood cancer (starts at 14:50). Dr. Nancy Sokol hosts.

Listen to the full podcast by pressing the Play Button below, or jump to the segment on sofosbuvir-velpatasvir for treatment of chronic HCV infection or the segment on neonatal phototherapy and risk of childhood cancer.

Dr. Di BisceglieDr. Adrian Di Bisceglie is Professor of Internal Medicine, Chairman of the Department of Internal Medicine, and Chief of Hepatology in the St. Louis University School of Medicine.
Dr. BhutaniDr. Vinod Bhutani is Professor of Pediatrics at Stanford University School of Medicine.

Segment on chronic HCV infection (Dr. Di Bisceglie):

  1. Feld JJ, Jacobson IM, Hézode C, et al. Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection. N Engl J Med 2015; 373:2599.
  2. Everson GT, Towner WJ, Davis MN, et al. Sofosbuvir With Velpatasvir in Treatment-Naive Noncirrhotic Patients With Genotype 1 to 6 Hepatitis C Virus Infection: A Randomized Trial. Ann Intern Med 2015; 163:818.
  3. Pianko S, Flamm SL, Shiffman ML, et al. Sofosbuvir Plus Velpatasvir Combination Therapy for Treatment-Experienced Patients With Genotype 1 or 3 Hepatitis C Virus Infection: A Randomized Trial. Ann Intern Med 2015; 163:809.

Segment on neonatal phototherapy (Dr. Bhutani):

  1. Newman TB, Wickremasinghe AC, Walsh EM, et al. Retrospective Cohort Study of Phototherapy and Childhood Cancer in Northern California. Pediatrics 2016; 137.
  2. Wickremasinghe AC, Kuzniewicz MW, Grimes BA, et al. Neonatal Phototherapy and Infantile Cancer. Pediatrics 2016; 137.

Close

Adrian M Di Bisceglie, MD Grant/Research/Clinical Trial Support: AbbVie [therapy of hepatitis C (ombitasvir, paritaprevir, dasabuvir )]; Bristol-Myers Squibb [therapy of hepatitis C (daclatasvir)]; Gilead [therapy of hepatitis C (sofosbuvir, ledipasvir)]. Consultant/Advisory Board: AbbVie [therapy of hepatitis C (ombitasvir, paritaprevir, dasabuvir )]; Bristol-Myers Squibb [therapy of hepatitis C (daclatasvir)]; Gilead [therapy of hepatitis C (sofosbuvir, ledipasvir)].

Vinod K Bhutani, MD, FAAP Nothing to disclose

Close

Pages